Galmed Pharmaceuticals (GLMD) Non Operating Income (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Non Operating Income of -$134000.0 for Q1 2026, up 16.25% year-over-year from -$115268.8 in Q1 2025, and down 128.94% quarter-over-quarter from $463000.0 in Q4 2025.
Galmed Pharmaceuticals (GLMD) Non Operating Income (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Non Operating Income history runs 14 years deep, the most recent figure standing at -$134000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 16.25% year-over-year to -$134000.0; the TTM figure through Mar 2026 stood at -$14000.0 (up 90.07% YoY), while the FY2025 annual figure was -$40000.0, up 62.62% from the prior year.
- Non Operating Income for Q1 2026 stood at -$134000.0, down from $463000.0 in the prior quarter.
- The five-year high for Non Operating Income was $468000.0 in Q4 2023, with the low at -$278000.0 in Q2 2023.
- The 5-year median for Non Operating Income is -$114500.0 (2024), against an average of -$14785.7.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income soared 122.47% in 2022, then tumbled 2040.0% in 2024.
- Galmed Pharmaceuticals' Non Operating Income stood at $51000.0 in 2022, then jumped by 817.65% to $468000.0 in 2023, then tumbled by 53.21% to $219000.0 in 2024, then jumped by 111.42% to $463000.0 in 2025, then slumped by 128.94% to -$134000.0 in 2026.
- Business Quant data shows GLMD's Non Operating Income at -$134000.0 in Q1 2026, $463000.0 in Q4 2025, and -$203000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134,000.00 |
| Dec 31, 2025 | 463,000.00 |
| Sep 30, 2025 | -203,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Mar 31, 2025 | -160,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | -97,000.00 |
| Jun 30, 2024 | -103,000.00 |
| Mar 31, 2024 | -126,000.00 |
| Dec 31, 2023 | 468,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -278,000.00 |
| Mar 31, 2023 | -172,000.00 |
| Mar 31, 2022 | 51,000.00 |
| Dec 31, 2021 | -40,000.00 |
| Sep 30, 2021 | -131,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | -227,000.00 |
| Dec 31, 2020 | -65,000.00 |
| Sep 30, 2020 | -685,000.00 |